Pipeline
Our focus on innovative product development for musculoskeletal pain and pain adjacencies is motivated by the unmet need in this space.
Advancing therapies for pain relief
Our pipeline reflects our deep commitment to advancing the science of non-opioid pain management and making Better Pain Management, Possible. Guided by science, and a patient centered mindset, we are advancing innovative therapies aimed at addressing unmet needs across acute and chronic pain pathways. By leveraging novel delivery technologies and our expertise in musculoskeletal pain and pain adjacencies, our goal is to expand treatment options that can potentially improve outcomes for patients while reducing reliance on opioids.
Our growing pipeline builds on our legacy of products for pain while investigating in therapies like gene therapy. By advancing both established and emerging therapeutic approaches, we remain committed to delivering pain management treatment where it matters most.
*Investigational products. Safety and Efficacy have not been established.
Looking for evidence?
Our medical information site includes a resource library for HCPs featuring the latest publications specific to our therapies.
Better
is Possible.
PCRX-201: Unlocking gene therapy to address pain and function
Knee OA is a serious disease in desperate need for innovation. PCRX-201 (enekinragene inzadenovec) is a gene therapy specifically designed to inhibit activation of inflammation caused by this disease and is being investigated to deliver long term pain relief and improved function.
Let’s innovate together
Collaboration drives progress, and we’re proud to work with organizations that share our vision for advancing pain management.